|
US6590079B2
(en)
*
|
1997-01-30 |
2003-07-08 |
Ixsys, Incorporated |
Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
|
|
US20010011125A1
(en)
*
|
1997-01-30 |
2001-08-02 |
William D. Huse |
Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use
|
|
US6596850B1
(en)
*
|
1998-01-30 |
2003-07-22 |
Ixsys, Incorporated |
Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
|
|
WO2000034780A2
(en)
*
|
1998-12-04 |
2000-06-15 |
Novartis Ag |
METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3?
|
|
US6521593B1
(en)
*
|
1999-02-01 |
2003-02-18 |
Childrens Hospital Los Angeles |
Methods for inhibiting brain tumor growth
|
|
US6531580B1
(en)
*
|
1999-06-24 |
2003-03-11 |
Ixsys, Inc. |
Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
|
|
MXPA02003420A
(es)
*
|
1999-10-06 |
2002-08-20 |
Basf Ag |
Inhibidores de la via de senalizacion de endotelina y antagonistas de los receptores de alfav°3 integrina para el tratamiento en combinacion.
|
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
AU2001238079A1
(en)
*
|
2000-02-09 |
2001-08-20 |
Med Immune, Inc. |
Antibody gene therapy with adeno-associated viral vectors
|
|
DK1259547T3
(da)
*
|
2000-03-01 |
2012-10-15 |
Medimmune Inc |
Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
|
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
CA2439852A1
(en)
*
|
2001-03-02 |
2002-09-12 |
Christine Dingivan |
Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
|
|
JP4660067B2
(ja)
*
|
2001-04-24 |
2011-03-30 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗血管新生剤とＴＮＦαとを用いる組合せ療法
|
|
EP1435967A2
(en)
*
|
2001-10-10 |
2004-07-14 |
Pharmacia Italia S.p.A. |
Methods for preventing and treating bone loss with steroid compounds
|
|
US7390885B2
(en)
|
2001-11-26 |
2008-06-24 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
|
US7365167B2
(en)
|
2001-11-26 |
2008-04-29 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
|
CA2478317A1
(en)
*
|
2002-03-04 |
2003-09-18 |
Medimmune, Inc. |
Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
|
|
WO2003075957A1
(en)
*
|
2002-03-04 |
2003-09-18 |
Medimmune, Inc. |
The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
|
|
CA2488441C
(en)
*
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
AU2004207003A1
(en)
*
|
2003-01-30 |
2004-08-12 |
Medimmune, Llc |
Anti-integrin alphanubeta3 antibody formulations and uses thereof
|
|
US20040208869A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
|
WO2004066956A2
(en)
*
|
2003-01-30 |
2004-08-12 |
Medimmune, Inc. |
Uses of integrin alphavbeta3 antagonists
|
|
GB0302699D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Univ Bradford |
Immunoglobulin
|
|
AU2004229501B2
(en)
|
2003-04-11 |
2011-08-18 |
Medimmune, Llc |
Recombinant IL-9 antibodies and uses thereof
|
|
US7351739B2
(en)
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
|
US8187595B2
(en)
|
2004-05-07 |
2012-05-29 |
The University Of North Carolina At Chapel Hill |
Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
|
|
EP1755660B1
(en)
*
|
2004-05-07 |
2010-03-24 |
The University of North Carolina at Chapel Hill |
Method for enhancing or inhibiting insulin-like growth factor-i
|
|
EP1778726A4
(en)
*
|
2004-08-16 |
2009-03-18 |
Medimmune Inc |
INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
|
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
EP1819732A2
(en)
|
2004-12-06 |
2007-08-22 |
Kirin Beer Kabushiki Kaisha |
Human monoclonal antibodies to influenza m2 protein and methods of making and using same
|
|
EP1907001B1
(en)
|
2005-06-17 |
2015-07-15 |
Merck Sharp & Dohme Corp. |
Ilt3 binding molecules and uses therefor
|
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
|
CA2655903A1
(en)
*
|
2006-06-19 |
2008-08-07 |
Tolerx, Inc. |
Ilt3 binding molecules and uses therefor
|
|
EP2043603A4
(en)
|
2006-07-11 |
2010-10-27 |
Arubor Corp |
PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
|
|
HUE048024T2
(hu)
|
2006-08-10 |
2020-05-28 |
Roy C Levitt |
Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
|
|
AU2007313300A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
|
EP2152300A4
(en)
*
|
2007-05-16 |
2012-12-05 |
Sinomab Bioscience Ltd |
FUNCTIONAL HUMANIZATION OF COMPLEMENTARITY-REGULATING REGIONS
|
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
US8633139B2
(en)
|
2007-12-21 |
2014-01-21 |
Abbvie Biotherapeutics Inc. |
Methods of screening complex protein libraries to identify altered properties
|
|
EP2303924B1
(en)
|
2008-06-16 |
2016-07-27 |
Patrys Limited |
Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
|
|
EP2437767B1
(en)
|
2009-06-01 |
2015-07-08 |
MedImmune, LLC |
Molecules with extended half-lives and uses thereof
|
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
|
WO2013098420A1
(en)
|
2011-12-28 |
2013-07-04 |
Immunoqure Ag |
Method of isolating human antibodies
|
|
CA2882757A1
(en)
|
2012-08-31 |
2014-03-06 |
The University Of North Carolina At Chapel Hill |
Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1)
|
|
JP6742237B2
(ja)
|
2013-07-03 |
2020-08-19 |
イムノキュア アーゲーＩｍｍｕｎｏｑｕｒｅ Ａｇ |
ヒト抗ｉｆｎ−アルファ抗体
|
|
MX2019011717A
(es)
|
2017-03-31 |
2019-12-16 |
Univ California |
Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos.
|
|
KR102098462B1
(ko)
*
|
2018-03-14 |
2020-04-08 |
가톨릭대학교 산학협력단 |
αvβ3 인테그린 표적 단일 도메인 항체
|
|
US20230092787A1
(en)
*
|
2020-02-17 |
2023-03-23 |
University Of Virginia Patent Foundation |
Car t cells targeting the integrin alphav beta3 exhibit robust anti-tumor responses against gliomas and other solid tumor malignancies
|